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Plasma levels of copeptin, a surrogate marker for the vasoconstrictor hormone arginine va-
sopressin (AVP), are increased in hemodialysis patients. Presently, it is unknown what
drives copeptin levels in hemodialysis patients. We investigated whether the established
physiological stimuli for copeptin release, i.e. plasma osmolality, blood volume and mean
arterial pressure (MAP), are operational in hemodialysis patients.
Methods
One hundred and eight prevalent, stable hemodialysis patients on a thrice-weekly dialysis
schedule were studied during hemodialysis with constant ultrafiltration rate and dialysate
conductivity in this observational study. Plasma levels of copeptin, sodium, MAP, and blood
volume were measured before, during and after hemodialysis. Multivariate analysis was
used to determine the association between copeptin (dependent variable) and the physio-
logical stimuli plasma sodium, MAP, excess weight as well as NT-pro-BNP immediately
prior to dialysis and between copeptin and changes of plasma sodium, MAP and blood vol-
ume with correction for age, sex and diabetes during dialysis treatment.
Results
Patients were 63±15.6 years old and 65% were male. Median dialysis vintage was 1.6
years (IQR 0.7–4.0). Twenty-three percent of the patients had diabetes and 82% had hyper-
tension. Median predialysis copeptin levels were 141.5 pmol/L (IQR 91.0–244.8 pmol/L).
Neither predialysis plasma sodium levels, nor NT-proBNP levels, nor MAP were associated
with predialysis copeptin levels. During hemodialysis, copeptin levels rose significantly
PLOS ONE | DOI:10.1371/journal.pone.0127116 May 14, 2015 1 / 12
OPEN ACCESS
Citation: Ettema EM, Kuipers J, Assa S, Bakker SJL,
Groen H, Westerhuis R, et al. (2015) Changes in
Plasma Copeptin Levels during Hemodialysis: Are
the Physiological Stimuli Active in Hemodialysis
Patients? PLoS ONE 10(5): e0127116. doi:10.1371/
journal.pone.0127116
Academic Editor: Daniel Schneditz, Medical
University of Graz, AUSTRIA
Received: January 5, 2015
Accepted: April 10, 2015
Published: May 14, 2015
Copyright: © 2015 Ettema et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All data underlying the
findings are within the paper and supporting
information file.
Funding: A grant of the Dutch Kidney Foundation
(Nierstichting) supported this work. The grant number
is C08.2279. The URL of the funder's website is www.
nierstichting.nl. The funders had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
(p<0.01) to 163.0 pmol/L (96.0–296.0 pmol/L). Decreases in blood volume and MAP were
associated with increases in copeptin levels during dialysis, whereas there was no signifi-
cant association between the change in plasma sodium levels and the change in
copeptin levels.
Conclusions
Plasma copeptin levels are elevated predialysis and increase further during hemodialysis.
Volume stimuli, i.e. decreases in MAP and blood volume, rather than osmotic stimuli, are
associated with change in copeptin levels during hemodialysis.
Introduction
Arginine vasopressin (AVP) is as vasoconstrictor hormone involved in blood pressure regula-
tion [1,2]. In hemodialysis patients, interdialytic plasma AVP levels are higher compared with
healthy individuals [3–6]. However, during hemodialysis, little or no increase in AVP levels
has been reported despite decreases in blood pressure and blood volume during most hemodi-
alysis sessions [7]. In the literature it has been speculated that deficient or inadequate release of
AVP could play a role in the pathogenesis of intradialytic hypotension [2,6,8].
Routine measurement of AVP is hampered by preanalytical variability and instability in
plasma, leading to short ex-vivo half-life [9,10]. Copeptin, the C-terminal part of the AVP pre-
cursor, is a more stable analyte and considered to be a good surrogate marker of AVP [11–13].
Like AVP, plasma levels of copeptin are increased in patients with chronic kidney disease and
in patients on hemodialysis compared with healthy individuals [14–16], in whom copeptin
ranges between 1 and 12 pmol/L [10]. Interestingly, higher copeptin concentration has been
identified as a strong risk marker for cardiovascular disease and mortality in hemodialysis pa-
tients [14–16].
Currently, it is unknown why hemodialysis patients have elevated AVP and copeptin levels.
It has been suggested that elevated predialysis plasma copeptin levels originate from the hemo-
dialysis treatment itself as a consequence of intradialytic volume depletion [14]. However, the
course of plasma copeptin levels during hemodialysis has not been studied before. Not only
hypovolemia, but also changes in blood pressure and plasma osmolality during hemodialysis
may influence the intradialytic course of copeptin levels [10]. The goal of this study was to ex-
plore whether the physiological stimuli for copeptin release as a surrogate marker of AVP, i.e.
changes in osmolality, blood volume and blood pressure, are operational in hemodialysis pa-
tients. We hypothesized that intradialytic decreases in blood volume and blood pressure and
an increase in plasma sodium concentration are associated with increases in copeptin. Know-
ing and understanding the course of copeptin levels during hemodialysis may help to elucidate
the mechanisms that lead to increased plasma copeptin levels in hemodialysis patients and un-
derstand the role of AVP during hemodialysis with respect to hemodynamic stability.
Methods
Patients
Included were patients from the University Medical Center Groningen and the Dialysis Center
Groningen who participated in an observational study on the prevalence and determinants of
hemodialysis-induced regional left ventricular systolic dysfunction [17]. Patients were eligible
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for study inclusion when they were 18 years or older, were on a thrice-weekly 4 hour hemodial-
ysis schedule and had been treated with hemodialysis for more than three months.
The study was performed in accordance with the principles of the Declaration of Helsinki
and was approved by the Medical Ethics Committee (METc) of the University Medical Center
Groningen. All patients gave written informed consent to the study, which was performed be-
tween March of 2009 and March of 2010.
Study protocol
Patients were studied at the first hemodialysis treatment of the week after the longest interdialytic
interval. Blood pressure and heart rate were measured using an automatic oscillometric monitor
that was incorporated in the hemodialysis apparatus at 30 minutes predialysis, every 30 minutes
during hemodialysis until 210 minutes on dialysis and post-dialysis after termination of the he-
modialysis session, including the return of the blood and removal of the dialysis needles.
Mean arterial blood pressure (MAP) was calculated as ((2xdiastolic blood pressure) + systol-
ic blood pressure)/3.
Blood samples for the analysis of plasma levels of copeptin, sodium and NT-proBNP were
collected from the arterial line at the initiation of hemodialysis, after 60 and 180 minutes on he-
modialysis and at the end of the hemodialysis treatment just before the return of the blood
from the extracorporeal circuit to the patient to exclude dilution by saline. Plasma samples
were stored at -80°C until analysis.
Excess weight at the start of hemodialysis was calculated as predialysis weight minus dry
weight of the individual patient. Prescriptions regarding dry weight were made by the nephrol-
ogists during their weekly visit to the participating patients. Dry weight was evaluated clinically
(peripheral edema, signs of pulmonary congestion, intradialytic and interdialytic blood pres-
sure course, muscle cramps) in combination with the cardio-thoracic ratio on chest radiogra-
phy, which is performed twice yearly as standard of care.
Hemodialysis treatment
All patients were on bicarbonate dialysis with a low-flux polysulfone hollow-fiber dialyser F8
(Fresenius Medical Care, Bad Hamburg, Germany). Blood flow and dialysate flow rates were
250–350 ml/min and 500 ml/min, respectively. Dialysate temperature was 36.0°C. Dialysate
composition was sodium 139 mmol/L, potassium 1.0 or 2.0 mmol/L, calcium 1.5 mmol/L,
magnesium 0.5 mmol/L, chloride 108 mmol/L, bicarbonate 34 mmol/L, acetate 3.0 mmol/L,
and glucose 1.0 g/dl.
Dialysate conductivity and ultrafiltration rate were kept constant during the dialysis session.
Patients received a light meal at 60 minutes on hemodialysis. Patients were dialyzed in su-
pine position which excluded an effect of posture changes on blood volume.
Laboratory procedures and definitions
Blood samples for the determination of copeptin were collected in ethylenediaminetetraacetic
acid (EDTA) tubes and copeptin was measured by a sandwich immunoassay (CT-proAVP
LIA; ThermoFisher Scientific, B.R.A.H.M.S. Biomarkers, Henningsdorf/Berlin, Germany) as
described previously [11,18]. Blood samples for the determination of sodium were collected in
heparin-coated tubes and measured with the indirect method of ion-selective electrode on a
Roche Modular (Hitachi, Tokyo, Japan). NT-proBNP was measured by the electrochemilumi-
nescence immunoassay (Roche Diagnostics, Mannheim, Germany). The change in blood vol-
ume was calculated from the change in hematocrit ([(Ht0/Ht1)-1]x100) with Ht0 representing
the hematocrit at the start of hemodialysis and Ht1 representing the hematocrit during
Stimuli for Copeptin in Hemodialysis Patients
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hemodialysis. Ultrafiltration rate was calculated by dividing ultrafiltration volume by dialysis
session length and target weight.
Diabetes mellitus was defined as fasting blood glucose>6 mmol/l or the use of antidiabetic
drugs. Hypertension was defined as a predialysis systolic blood pressure>140 mmHg and/or a
diastolic blood pressure>90 mmHg or the use of antihypertensive drugs. Cardiovascular histo-
ry was defined as any history of ischemic heart disease, congestive heart failure, coronary artery
bypass grafting, percutaneous coronary intervention, stroke or peripheral vascular disease. The
presence of residual renal function was indicated by urinary volume200 ml/day.
Statistical analysis
Normally distributed variables are reported as mean ± SD. Variables with a skewed distribution
are presented as median and interquartile range (IQR). Categorical data is reported as number
and percentage. Continuous variables were analyzed with OneWay ANOVA (post-hoc test with
Bonferroni correction), paired t-test, Wilcoxon Signed Rank test andWilcoxon Ranked Sum
(Mann-Whitney U) test when appropriate. Categorical variables were analyzed with the Kruskal-
Wallis test. Non-normally distributed variables were transformed to achieve normality.
Baseline characteristics are given for the overall population and according to tertiles of
copeptin concentration. Plasma copeptin tertiles were stratified for gender since gender is
known to affect plasma copeptin levels [11]. Correlations were calculated using Spearmans’
rho for skewed data.
Multiple regression analysis was used to analyze the association between the putative stimuli
of copeptin release and (changes in) plasma copeptin levels. In these analyses, postdialysis val-
ues of copeptin, MAP and sodium were corrected for the baseline value. Effects of these vari-
ables were corrected for factors selected from the univariate comparison, based on a p-value
<0.157 using backward stepwise selection as advised in literature [19]. To test the robustness
of our findings various sensitivity analyses were performed. First, we investigated the intradia-
lytic course of copeptin with a correction for hemoconcentration. Second, we tested whether
changes in copeptin levels differed between diabetic and non-diabetic patients and between pa-
tients with and without residual diuresis by inserting an interaction term for diabetes and resid-
ual diuresis, respectively, and the stimuli of copeptin in the multivariable models. Analyses
were performed with SPSS version 20.0 and GraphPad Prism version 5.0. P-values of<0.05
(two-tailed) were considered statistically significant.
Results
Patients
Characteristics of participating patients are shown in Table 1. The mean (±SD) age was
63 ± 15.6 years and 65% were male (Table 1). The median dialysis vintage was 1.6 years (IQR
0.7–4.0) and 41% of the patients had residual diuresis. Twenty-three percent of the patients
had diabetes mellitus and 82% of the patients had hypertension. Causes of renal failure were
hypertension (n = 18), diabetes mellitus (n = 14), autosomal dominant polycystic kidney dis-
ease (n = 14), glomerulonephritis (n = 13), focal segmental glomerulosclerosis (n = 10), chronic
obstructive nephropathy (n = 6), IgA nephropathy (n = 4), chronic pyelonephritis (n = 3) and
miscellaneous causes (n = 17) or unknown etiology (n = 9).
Predialysis copeptin levels and physiological stimuli
The median predialysis plasma copeptin level was 141.5 pmol/L (IQR 91.0–244.8). Males had
significantly higher plasma copeptin levels than females (161.5 (IQR 104.8–254.3) pmol/L
Stimuli for Copeptin in Hemodialysis Patients
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versus 107.0 (IQR 34.9–182.8) pmol/L, respectively; p = 0.02). Patients in the first (lowest) ter-
tile of copeptin levels were significantly older than the patients in the second and third (high-
est) tertile (Table 1) and there was a significant correlation between predialysis copeptin levels
and age (Spearman’s r = -0.261; p = 0.01).
When adjusted for age, sex and diabetes, there was no association of predialysis copeptin
levels with predialysis plasma sodium concentration, MAP, excess weight at the start of hemo-
dialysis and NT-proBNP levels. If associations of plasma sodium concentration, MAP, excess
weight at the start of hemodialysis and NT-proBNP levels were also adjusted for each other
Table 1. Patient characteristics according to sex-stratified tertiles of predialysis copeptin levels.





pmol/L; F: >59.5 to
161.0 pmol/L





N N N N
Age, years 63 ± 15.6 108 69 ± 14.9 35 59 ± 15 37 60 ± 15 36 0.01**
Male 70 (65) 108 23/12 (65.7/34.3) 35 24/13 (64.9/35.1) 37 23/13 (63.9/36.1) 36 0.9
Dialysis vintage, years 1.6 [0.7–4.0] 108 1.8 [0.7–4.1] 35 1.2 [0.4–3.5] 37 2.0 [0.9–4.2] 36 0.11
Residual diuresis 39 (40.6) 96 14 (46.7) 30 17 (50.0) 34 8 (25.0) 32 0.09
BMI, kg/m2 25.9 ± 4.4 108 25.4 ± 4.1 35 26.6 ± 4.9 37 25.6 ± 4.1 36 0.45
Diabetes mellitus 25 (23.1) 108 4 (11.4) 35 10 (27.0) 37 11 (30.6) 36 0.13
HbA1c, % 5.4 [5.0–6.0] 89 5.4 [5.1–5.7] 28 5.4 [5.2–5.9] 34 5.6 [4.9–6.4] 27 0.63
Hypertension 89 (82.4) 108 30 (85.7) 35 32 (86.5) 37 27 (75.0) 36 0.36
Cardiovascular history 25 (23.1) 108 10 (28.6) 35 5 (13.5) 37 10 (27.8) 36 0.23
Ultraﬁltration volume, mL 2549 ± 779 108 2396 ± 796 35 2679 ± 641 37 2565 ± 882 36 0.31
Ultraﬁltration rate (mL/kg/
h)
8.5 ± 2.6 108 8.5 ± 2.9 35 8.4 ± 2.1 37 8.7 ± 2.8 36 0.82
Medication
ACEi 10 (9.4) 108 2 (1.9) 34 3 (2.8) 36 5 (4.7) 36 0.50
ARB 14 (13) 7 (6.8) 35 3 (2.5) 37 4 (3.7) 36 0.30
Beta blocker 62 (57.4) 21 (19.4) 35 19 (17.6 37 22 (20.4) 36 0.66
CCB 14 (13.2) 7 (6.6) 34 5 (4.7) 36 2 (1.9) 36 0.18
Diuretics 8 (7.5) 3 (2.8) 34 5 (4.7) 36 0 (0) 36 0.08
Statins 20 (18.9) 7 (6.5) 34 5 (4.7) 36 8 (7.5) 36 0.64
Aspirin 58 (54.7) 22 (20.8) 34 18 (17.0) 36 18 (17.0) 36 0.37
Excess weight, kg 2.2 [1.3–3.3] 108 1.9 [1.0–2.9] 35 2.4 [1.9–3.6] 37 2.4 [1.2–3.3] 36 0.10
SBP, mmHg 140 ± 25 107 144 ± 24 35 143 ± 22 36 134 ± 28 36 0.15
DBP, mmHg 80 ± 16 107 78 ± 15 35 83 ± 15 36 79 ± 19 36 0.49
MAP, mmHg 100 ± 18 107 100 ± 15 35 103 ± 16 36 97 ± 21 36 0.41
Plasma sodium, mmol/l 138 ± 3 106 138 ± 3 35 138 ± 4 37 139 ± 2 34 0.44









Continuous variables are represented as mean ± SD, skewed variables as median and interquartile range (IQR) and categorical variables as number and
percentage within tertile. The number of the included patients is indicated.
* P-value indicates differences between tertiles.
** Post-hoc test of age showed a signiﬁcant difference between tertile 1 and 2 (p = 0.02) and between tertile 1 and 3 (p = 0.03).
Abbreviations: BMI: body mass index; DBP: diastolic blood pressure; F: females; M: males; MAP: mean arterial blood pressure; NT-proBNP: N-terminal
pro-brain natriuretic peptide; SBP: systolic blood pressure.
doi:10.1371/journal.pone.0127116.t001
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(fully adjusted model), a trend was seen for an association of predialysis plasma copeptin levels
with predialysis MAP and levels of NT-proBNP (Table 2).
Intradialytic change of plasma copeptin levels and physiological stimuli
The courses of the intradialytic change in copeptin, MAP, blood volume, and plasma sodium
are shown in Fig 1. During hemodialysis, systolic blood pressure decreased from 140±25 mmHg
predialysis to 126±25 mmHg at 210 minutes on dialysis and to 132±26 mmHg postdialysis. Dia-
stolic blood pressure decreased from 80±16 mmHg predialysis to 71±16 mmHg at 210 minutes
on dialysis and to 73±14 mmHg postdialysis andMAP decreased from 101±18 mmHg predialy-
sis to 90±17 mmHg at 210 minutes on dialysis and to 93±16 mmHg postdialysis (all p<0.01).
There was only a modest, but significant, increase in heart rate during hemodialysis (from 74±
14 to 77±14 bpm at 210 minutes on dialysis and to 80±16 bpm postdialysis, both p<0.01). Rela-
tive blood volume decreased significantly during hemodialysis (to -4.4±5.3%; p<0.01). Plasma
sodium levels increased slightly but significantly during hemodialysis (from 138.2±3.3 mmol/L
predialysis to 138.8±1.9 mmol/L postdialysis; p<0.05).
Plasma copeptin levels increased significantly during hemodialysis: from 141.5 pmol/L
(IQR 91.0–244.8) to 148.0 pmol/L (93.0–254.0) at 60 minutes intradialysis, to 155.0 pmol/L
(93.9–279.0) at 180 minutes intradialysis and to 163.0 pmol/L (96.0–296.0) at the end of dialy-
sis (p<0.01 for the overall change).
Multivariate analysis showed a significant association of the intradialytic change in copeptin
and the change in MAP and blood volume when adjusted for age, sex, diabetes and predialysis
copeptin levels. These associations remained significant when we additionally adjusted for
plasma sodium concentration and MAP (Table 3). In contrast, change in plasma sodium was
not associated with change in copeptin during hemodialysis.
Sensitivity analyses
To exclude a possible effect of ultrafiltration-induced intravascular volume change on the
intradialytic change in plasma copeptin levels, we corrected the intradialytic course of plasma
copeptin levels for hemoconcentration according to Schneditz et al [20]. Despite this, the in-
crease in plasma copeptin levels during hemodialysis remained significant (p<0.01). When the
change in relative blood volume was calculated based on the change in albumin as an alterna-
tive marker of hemoconcentration, results of the multivariate analysis remained similar (data
not shown).
Table 2. Predialysis association between putative determinants and plasma copeptin levels.
Determinants Multivariate linear regression
Model 1 Model 2
B Betastandardized CI P-value B Betastandardized CI P-value
Predialysis sodium (mmol/l) 0.134 0.098 -0.121; 0.390 0.30 0.183 0.131 -0.081; 0.448 0.17
Predialysis MAP (mmHg) -0.022 -0.086 -0.071; 0.027 0.37 -0.045 -0.165 -0.098; 0.008 0.09
Excess weight at start of dialysis (kg) 0.062 0.006 -1.989; 2.113 0.9 0.464 0.044 -1.691; 2.618 0.67
Predialysis NT-proBNP (ng/l) 0.525 0.152 -0.120; 1.170 0.11 0.612 0.177 -0.049; 1.273 0.07
Model 1: adjustment for age, sex and diabetes.
Model 2: as model 1 and additionally adjusted for the other determinants included in this model.
Abbreviations: CI: conﬁdence interval of B; MAP: mean arterial pressure; NT-proBNP: N-terminal pro-B type natriuretic peptide.
doi:10.1371/journal.pone.0127116.t002
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The results of the multivariate analyses remained similar for the intradialytic change in
MAP (βstandardized = -0.051, p = 0.04) and plasma sodium (βstandardized = -0.007, p = 0.80), but,
as to be expected, the change in blood volume was no longer significantly associated with
change in copeptin levels (βstandardized = 0.021, p = 0.31).
Although predialysis plasma copeptin levels were higher in diabetic patients in comparison
with non-diabetic patients (188.0 pmol/L (IQR 119.5–284.0) versus 131.0 pmol/L (IQR 85.0–
242.0), respectively (p = 0.06), plasma copeptin levels increased significantly and to the same
extent in both diabetic (+12.8%) and non-diabetic (+13.0%) patients to 212.0 pmol/L (IQR
125.5–319.5) and 148.0 pmol/L (IQR 82.7–283.3), respectively. To assess whether diabetic and
non-diabetic patients respond in a similar fashion to the physiological volume, pressure and os-
motic stimuli, we also tested whether there was an interaction between the determinants of
copeptin during hemodialysis and diabetes. No statistically significant interactions for diabetes
status with plasma sodium concentration, MAP or blood volume were found.
Fig 1. Intradialytic course of the change in copeptin, mean arterial pressure, blood volume and plasma sodium levels (%). Depicted are median and
interquartile range (IQR) for copeptin and sodium and mean and 95% confidence intervals for MAP and blood volume. #Denotes p<0.05 compared with the
predialysis value. *Denotes p<0.01 compared with the predialysis value.
doi:10.1371/journal.pone.0127116.g001
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Thirty-nine patients had residual diuresis. Plasma copeptin levels tended to be higher in pa-
tients without residual diuresis compared with patients with residual diuresis (167.0 pmol/L
(IQR 95.3–261.0) versus 134.0 pmol/L (IQR 85.2–187.0); p = 0.09) and predialysis copeptin
levels correlated significantly with residual diuresis; the higher daily residual urinary produc-
tion, the lower predialysis plasma copeptin levels (Spearman’s r = -0.246; p = 0.02). On the
other hand, there was no correlation between predialysis copeptin levels and dialysis vintage
(Spearman’s r = 0.071; p = 0.47). To assess whether patients with and without residual diuresis
respond similarly to the physiological volume, pressure and osmotic stimuli, we also tested
whether there was an interaction between the determinants of copeptin during hemodialysis
and residual diuresis. No statistically significant interactions were found between for residual
diuresis and plasma sodium concentration, MAP and blood volume. Results were similar when
residual renal clearance instead of residual diuresis was used in the analyses (data not shown).
Discussion
The present study shows that plasma copeptin levels are elevated predialysis and rise during
hemodialysis. Volume stimuli, i.e. decreases in blood pressure and blood volume, rather than
the change in plasma sodium level as an osmotic stimulus, were significantly associated with
the intradialytic change in plasma copeptin levels.
In this study, predialysis plasma copeptin levels were markedly elevated in comparison with
healthy persons [11,21]. This is in agreement with the findings of other studies in hemodialysis
patients [14,16]. In our cohort, predialysis plasma copeptin levels were even higher than in
these previous studies [14,16]. This could be explained by differences in patient characteristics,
in particular a longer dialysis vintage in our study as compared with previous studies in hemo-
dialysis patients [14,16]. In these studies, a significant association between higher predialysis
plasma copeptin levels and a longer dialysis vintage was found. If the in-vivo half life of copep-
tin is long enough, the dialysis procedure itself could lead to accumulation since copeptin in-
creased during hemodialysis, as is shown in this study, resulting in gradually increasing
copeptin levels in the long-term. This could especially be the case with low-flux hemodialysis,
as was used in the present study since one would expect less removal of copeptin with low-flux
hemodialysis in comparison with high-flux hemodialysis [16]. In addition, it has been sug-
gested that the high predialysis copeptin levels are attributable to accumulation due to impaired
renal clearance [14,16]. Our finding of an inverse correlation between predialysis copeptin and
residual diuresis and residual clearance supports this assumption. In non-dialysis patients with
Table 3. Association between the intradialytic change in the putative stimuli and the change in plasma copeptin levels during hemodialysis.
Determinants Multivariate linear regression
Model 1 Model 2
B Betastandardized CI P-value B Betastandardized CI P-value
Δ sodium (mmol/l) -0.028 -0.010 -0.157; 0.100 0.66 -0.003 -0.001 -0.157; 0.150 0.9
Δ MAP (mmHg) -0.025 -0.083 -0.045; -0.005 0.02 -0.015 -0.051 -0.030; 0.000 0.04
Δ RBV (%) -0.049 -0.050 -0.085; -0.014 0.01 -0.057 -0.057 -0.098; -0.016 0.01
Model 1: adjustment for age, sex, diabetes and predialysis copeptin levels.
Model 2: as model 1 and additionally adjusted for the other determinants included in this model.
Δ: from predialysis to postdialysis for sodium and RBV, for predialysis to 210 minutes intra-dialysis for MAP, with correction for predialysis sodium and
predialysis MAP.
Abbreviations: CI: conﬁdence interval of B; MAP: mean arterial pressure; RBV: relative blood volume.
doi:10.1371/journal.pone.0127116.t003
Stimuli for Copeptin in Hemodialysis Patients
PLOS ONE | DOI:10.1371/journal.pone.0127116 May 14, 2015 8 / 12
chronic kidney disease [15] and healthy men [21] also an inverse correlation between eGFR
and copeptin was found. It is not clear if AVP is also affected by renal function and to what ex-
tent in comparison with copeptin. The higher proportion of males in our study as compared
with the other two studies probably also contributed to the higher copeptin levels. It has previ-
ously been shown in healthy individuals that males have higher copeptin levels than females
[11,21]. To our knowledge, our study is the first to show that this is also the case in
hemodialysis patients.
We observed a trend for the association between predialysis copeptin levels and NT-
proBNP levels and MAP. In previous studies, a significant association between copeptin and
NT-proBNP was found [14,16]. In contrast, the finding of a trend for the association between a
lower MAP and higher copeptin concentrations is not in line with previous studies, in which a
weak but significant correlation was observed between higher systolic blood pressure and
higher copeptin levels by Fenske et al [14], while Artunc et al did not find any association be-
tween predialysis copeptin levels and blood pressure [16]. These divergent associations could
be explained by differences in predialysis blood pressure, volume status and the proportion of
patients with diabetes mellitus.
The suggestion that the dialysis procedure itself could contribute to the markedly elevated
copeptin levels that are observed in hemodialysis patients has been proposed previously by
Fenske et al. This group suggested that volume depletion during hemodialysis might be respon-
sible for the elevated AVP levels in hemodialysis patients [14]. Notably, such a hemodialysis-
associated increase in copeptin levels can only contribute to elevated predialysis copeptin levels
if the half-life of copeptin is relatively long. Unfortunately, data on the in-vivo half-life of
copeptin are lacking in hemodialysis patients. If future studies would confirm that the in-vivo
half life of copeptin is long enough, allowing the hemodialysis procedure to significantly con-
tribute to elevated predialysis copeptin levels in hemodialysis patients, this might explain, at
least in part, the association between elevated plasma copeptin levels and adverse outcome.
Large reductions in blood pressure during hemodialysis [22,23] and higher ultrafiltration rates
[24], probably translating in more pronounced hypovolemia, are associated with a greater risk
of all-cause mortality and cardiovascular events. As this study shows, intradialytic reductions
in blood pressure and blood volume are also associated with a rise in copeptin levels and
copeptin, in turn, is associated with an increased risk for cardiovascular events and all-cause
mortality in hemodialysis patients [14]. It remains to be studied whether copeptin is merely a
marker of hemodynamic stress induced by hemodialysis, or contributes to the increased risk
for adverse events in hemodialysis patients.
This is the first study that measured copeptin levels not only before but also during and at
the end of hemodialysis. We noted that plasma copeptin levels rose significantly during hemo-
dialysis and that the increase remained significant with correction for hemoconcentration as a
result of ultrafiltration. The significant association between decreases in blood pressure and
blood volume and a rise in copeptin levels indicates that the physiological pressure and volume
stimuli for the release of copeptin and thus of AVP are active in hemodialysis patients. Thus, it
is unlikely that deficient or inadequate AVP release during hemodialysis is explained by a lack
of stimuli during hemodialysis or by insensitivity of the hypothalamus-pituitary-axis, at least
not in this cohort. Since copeptin behaves similarly to AVP in the circulation [10], one would
expect AVP also to increase during hemodialysis. However, the intradialytic increase of plasma
AVP as well as plasma copeptin could well be underestimated as copeptin and AVP are proba-
bly removed by dialysis [25] considering its molecular weights of about 5 kDa (11,15] and 1
kDa [26], respectively. Presently, there are no data on the dialyzability of copeptin nor AVP
and future studies should investigate whether copeptin and AVP are indeed removed by
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hemodialysis and if so to what extent. Whether the intradialytic courses of copeptin and AVP
are similar also remains to be studied.
In this study, plasma sodium levels increased slightly but significantly during hemodialysis
with a dialysate sodium concentration of 139 mmol/l. Remarkably, we found no significant as-
sociation between the change in copeptin levels and changes in plasma sodium during hemodi-
alysis. Under normal physiological conditions, the secretion of AVP, and thus copeptin, is
mainly regulated by changes in plasma osmolality [27–30]. However, in hypotensive states,
plasma AVP release is thought to be mainly controlled by the baroreceptorreflex [27] and, in
such situations, changes in blood volume may play a more important role in AVP release [28].
On the other hand, we should be cautious with conclusions on the absence of a significant asso-
ciation between the change in plasma sodium concentration and copeptin levels. First, the
overall change of plasma sodium concentration was modest. Second, since we did not measure
plasma glucose levels, we could not calculate the effective plasma osmolality and, thus, could
not relate changes in plasma osmolality with changes in copeptin levels. However, when we an-
alyzed diabetic and non-diabetic patients separately, we found that plasma copeptin levels rose
significantly and to the same extent in both groups. Furthermore, there was no statistically sig-
nificant interaction between diabetes status and plasma sodium concentration, MAP and blood
volume in their associations with the change in copeptin concentration. A drawback of the
present study is that an objective marker of volume status, like bioimpedance analysis, is lack-
ing. It is intriguing that higher copeptin levels prior to dialysis tended to be associated with
higher plasma levels of the volume marker NT-proBNP, whereas during hemodialysis a de-
crease in relative blood volume was associated with a significant increase in plasma copeptin
levels. The former was also found previously: the more volume overloaded patients were, the
higher plasma copeptin levels were [14]. We have no explanation for this apparent paradox.
Copeptin might also be a volume marker in steady state situations, i.e. before hemodialysis and
in the interdialytic interval. More studies on the course of copeptin in the intra- and interdialy-
tic interval are needed.
Conclusion
Plasma copeptin levels are increased predialysis and show a significant increase during hemo-
dialysis. Intradialytic decreases in blood pressure and blood volume were associated with an in-
crease in plasma copeptin. Thus, volumetric stimuli for copeptin release, i.e. decreases in blood
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